Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATM V1841I |
| Therapy | Olaparib |
| Indication/Tumor Type | neuroblastoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM V1841I | neuroblastoma | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment decreased viability of transformed neuroblastoma cells expressing ATM V1841I in culture (PMID: 29059438). | 29059438 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29059438) | Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. | Full reference... |